Abstract
GH/IGF-I axis activity changes have been reported both in anorexia nervosa (AN) and in obesity (OB). AN is characterized by GH hypersecretion and very low IGF-I levels as a result of undernutrition and acquired peripheral GH resistance. On the other hand OB is a GH hyposecretory state but IGF-I levels are generally preserved. The activity of GH/IGF-I axis in AN and OB has never been directly compared with that of other pathophysiological condi tions such as hypopituitarism and critical illness in which a reduction of both GH and IGFsecretion has been demonstrated. To this aim, we evaluated IGF-I levels and both basal and GHRH (1 μg/kg) IV-induced GH secretion in 20 female patients with anorexia nervosa (mean age: 19.1±0.8 years) and in 15 female and 5 male patients with simple obesity (mean age 39.0±3.0 years). We then compared the results with those of hypopituitaric patients with severe GH deficiency (GHD), including 10 female and 10 male patients (mean age: 32.0±2.1 years), and with 4 female and 7 male patients with critical illness (CRI) following multiple trau ma 72 hours after ICU admission (mean age: 59.2±1.2 years). Twenty-six normal subjects (NS including 14 female and 12 male patients (mean age: 37.8±3.7 years) were studied as controls Basal IGF-I levels in AN patients (93.5±11 μg/L) were lower (p<0.001) than in the NS (201.7±13.5 μg/L) and OB (194.5±28.6 μg/L), which, in turn, were similar. IGF-I levels in AN patients were lower than in CRI patients (162.8±17.4 μg/L) and higher than in GHD patients (76.7±13.5 μg/L) but these differences did not attain statistical significance. Basal GH levels in AN patients (7.6±2.5 μg/L) were higher (p<0.001) than in NS (1.8±0.3 μg/L), OB patients (1.1±0.5 μg/L), CRI patients (1.8±0.5 μg/L) and GHD patients (0.3±0.1 μg/L), which were the lowest (p<0.01). The GHRH-induced GH rise in AN patients (AUC: 2032.9±253.5 μg/L/h) was three fold higher (p<0.001) than in NS (662.1±80.3 μg/L). On the other hand in OB (332.4±74.7 μg/L/h) the GH response to GHRH was similar to that in CRI (199.6±98.8 μg/L/h); both were clearly higher (p<0.01) than in GHD patients (25.1±5.2 μg/L/h) but lower (p<0.01) than in NS These findings demonstrate that in AN patients, in spite of a clear increase of both basal and GHRH-induced GH secretion, IGF-I synthesis and release are as markedly impaired as in patients with panhypopituitarism and severe GHD. On the other hand in OB and in CRI, IGFsynthesis and release are preserved despite marked impairment to GHRH-induced GH secre tion. These results reinforce the major role of nutrition in conditioning the activity of GH/IGFaxis in different patho-physiological states.
Similar content being viewed by others
References
Ross R.J.M., Chew S.L.: Acquired growth hormone resistance. Eur. J. Endocrinol., 132, 655–660, 1995.
Phillips L.S., Unterman T.G.: Somatomedin activity in disorders of nutrition and metabolism. Clin. Endocrinol. Metab., 13, 145–180, 1995.
Donaghy A.J., Baxter R.C.: Insulin-like growth factor bioactivity and its modification in growth hormone resistant states. In: Ross R.J.M., Savage M.O. (Eds.), Bailliere’s Clinical Endocrinology and Metabolism, Growth hormone resistance. London, WB Saunders, 1996, p. 421–447.
Berelowitz M., Szabo M., Frohman L.A., Firestone S., Chu L.: Somatomedin C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science, 212, 1279–1281, 1981.
Ceda G.P.: IGFs in the feedback control of GH secretion: hypothalamic and/or pituitary action? J. Endocrinol. Invest., 18, 734–737, 1995.
Tamai H.T., Komaki G., Matsubayashi S., Kobayashi N., Mori K., Nakagawa T., Truong M.P., Walter R.M. jr., Kumagai L.F.: Effect of cholinergic muscarinic receptor blockade on human growth hormone (GH)-releasing hormone-(1-44)-induced-GH secretion in anorexia nervosa. J. Clin. Endocrinol. Metab., 70, 738–741, 1990.
Rolla M., Andreoni A., Belliti D., Cristofani R., Federghini M., Muller E.E.: Blockade of cholinergic muscarinic receptors by pirenzepine and GHRH-induced GH secretion in the acute and recovery phase of anorexia and atypical eating disorders. Biol. Psychiatry, 29, 1079–1091, 1991.
Ghigo E., Arvat E., Gianotti L., Nicolosi M., Valetto M.R., Avagnina S., Bellitti D., Rolla D., Muller E.E., Camanni F.: Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa. Biol. Psychiatry, 36, 689–695, 1994.
Gianotti L., Arvat E., Valetto M.R., Ramunni J., Di Vito L., Maccagno B., Camanni F., Ghigo E.: Effects of beta-adrenergic agonists and antagonists on the GH response to GHRH in anorexia nervosa. Biol. Psychiatry, 43, 181–187, 1998.
Glass A.R.: Endocrine aspects of obesity. Med. Clin. North Am., 73, 139–160, 1989.
Veldhuis J.D., Iranmanesh A., Ho K.K.Y., Waters M.J., Johnson M.L., Lizarralde G.: Dual effects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J. Clin. Endocrinol. Metab., 72, 51–59, 1991.
Hochberg Z., Hertz P., Colin V., Ish-shalom S., Yeshurun D., Youdim M.B.H., amit T.: The distal axis of growth hormone (GH) in nutritional disorder: GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF-I receptors in obesity and anorexia nervosa. Metabolism, 41, 106–112, 1992.
Caufriez A., Golstein J., Lebrun P., Herchuelz A., Furlanetto R., Copinschi G.: Relations between immunoreactive somatomedin C, insulin and T3 patterns during fasting in obese subjects. Clin. Endocrinol., 20, 65–70, 1984.
Rassmussen M.H., Frystyk J., Andersen T., Breum L., Christiansen J.S., Hilsted J.: The impact of obesity, fat distribution and energy restriction on insulin-like growth factor I (IGFI), IGF-binding protein-3, insulin and growth hormone. Metabolism, 43, 315–319, 1994.
Copeland K.C., Colletti R.B., Devlin J.T., McAuliffe T.L.: The relationship between insulin-like growth factor I, adiposity, and aging. Metabolism, 39, 584–587, 1990.
Maccario M., Valetto M.R., Savio P., Aimaretti G., Baffoni C., Procopio M., Grottoli S., Oleandri S.E., Arvat E., Ghigo E.: Maximal secretory capacity of somatotrope cells in obesity: comparison with GH deficiency. Int. J. Obes., 21, 27–32, 1997.
Tannenbaum G.S., Lapointe M., Gurd W., Finkelstein J.A.: Mechanisms of impaired growth hormone secretion in genetically obese Zucker rats: roles of growth hormone-releasing factor and somatostatin. Endocrinology, 127, 3087–3095, 1990.
Taylor L.M., Blackard W.G.: Effects of lipids on growth hormone synthesis by isolated pituitaries. Proceedings of the Society for Experimental Biology & Medicine, 73, 765–770, 1971.
Renier G., Abribat T., Brazeau P., Deslauriers P., Gradeau P.: Cellular mechanism of caprylic acid-induced growth hormone suppression. Metabolism, 39, 1108–1112, 1990.
Thissen J.P., Ketelslegers J.M., Underwood L.E.: Nutritional regulation of the insulin-like growth factors. Endocr. Rev., 15, 80–101, 1994.
Froesch E.R., Guler H.P., Schmid C., Bink K., Zapf J.: Therapeutic potential of insulinlike growth factor I. Trends Endocrinol. Metab., 1, 254–260, 1990.
Underwood L.E., Van Wyk J.J.: Normal and aberrant growth. In: Wilson J.D., Foster D.W. (Eds.), Williams Textbook of Endocrinology, ed. 8. Philadelphia, Saunders Co, 1992, p. 1079.
Cuneo R.C., Salomon F., Mc Gauley G.A., Sonksen P.H.: The growth hormone deficiency syndrome in adults. Clin. Endocrinol., 37, 387–397, 1992.
Van den Berghe G., de Zegher F., Lauwers P.: Growth hormone secretion in critical illness: effects of dopamine. J. Clin. Endocrinol. Metab., 79, 1141–1146, 1994.
Melarvie S., Jeevanandam M., Holaday N.J., Petersen S.R.: Pulsatile nature of growth hormone levels in critical ill trauma victims. Surgery, 117, 402–408, 1995.
Wilmore D.W.: Catabolic illness. Strategies for enhancing recovery. N. Engl. J. Med., 325, 695–702, 1991.
Sassolas G.: Potential therapeutic applications of growth hormone in adults. Horm. Res., 42, 72–78, 1994.
Voerman B.J., Strack van Schijndel R.J.M., Groeneveld A.B.J., de Boer H., Nauta J.P., Thijs L.G.: Recombinant human growth hormone in critically ill nonseptic patients: results from a randomized, placebo-controlled trial. Crit. Care Med., 23, 665–672, 1995.
Pichard C., Kyle U., Chevrolet J.C., Jolliet P., Slosman D., Mensi N., Temler E., Ricou B.: Lack of effects of recombinant growth hormone on muscle function in patients requiring prolonged mechanical ventilation: a prospective, randomized, controlled study. Crit. Care Med., 6, 403–413, 1996.
Phillips L.S., Young H.S.: Nutrition and somatomedin I. Effect of fasting and refeeding on serum somatomedin activity and cartilage growth activity in rats. Endocrinology, 99, 304–310, 1976.
Merimee T.J., Fineberg S.E.: Dietary regulation of human growth hormone secretion. Metabolism, 22, 1491–1497, 1973.
Clemmons D.R., Klibanski A., Underwood L.E., Mc Arthur J.W., Ridgway E.C., Beitius I.Z., Van Wyk J.J.: Reduction of plasma immunoreactive somatomedin C during fasting in humans. J. Clin. Endocrinol. Metab., 53, 1247–1250, 1981.
Jones J.I., Clemmons D.R.: Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev., 16, 3–34, 1995.
Clemmons D.R., Underwood L.E.: Nutritional regulation of IGF-I and IGF binding proteins. Annu. Rev. Nutr., 11, 393–412, 1991.
Houston B., O’Neill I.E.: Insulin and growth hormone act sinergistically to stimulate insulin-like growth factor-I production by cultured chicken hepatocytes. J. Endocrinol., 128, 389–393, 1991.
Clemmons D.R., Van Wyk J.J.: Factors controlling blood concentration of somatomedin C. Clin. Endocrinol. Metab., 13, 113–143, 1984.
Ghigo E., Aimaretti G., Gianotti L., Bellone J., Arvat M., Camanni F.: New approach to the diagnosis of growth hormone deficiency in adults. Eur. J. Endocrinol., 134, 352–356, 1996.
Muller E.E., Brambilla F.: Disordini del comportamento alimentare. Anoressia e bulimia nervosa. Roma-Milano, Pythagora Press, 1990.
Maccario M., Procopio M., Grottoli S., Oleandri S.E., Boffano G.M., Taliano M., Camanni F., Ghigo E.: Effects of Acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity. Metabolism, 45, 1–6, 1996.
Van den Berghe G., de Zegher F., Veldhuis J.D., Wouters P., Awouters M., Verbruggen W., Schetz M., Verwaest C., Lauwers P., Bouillon R., Bowers C.Y.: The somatotropic axis in critical illness: effect of continous growth hormone (GH)-releasing hormone and GH-relasing peptide-2 infusion. J. Clin. Endocrinol. Metab., 82, 590–595, 1997.
Gianotti L., Broglio F., Arvat E., Pittoni G., Gallioli G., Zanello M., Colombo S., Marian F., Picarone M., Minuto F., Papini M.G., Boghen M.F., Miola C., Ghigo E.: GH/IGF-I axis in catabolic patients with sepsis or trauma. 79th Annual Meeting of The Endocrine Society, Minneapolis June 11-14 1997, Abs P1-109.
Dieguez C., Page M.D., Scanlon M.F.: Growth regulation and its alteration in disease states. Clin. Endocrinol., 28, 109–143, 1988.
Jenkins R.C., Ross R.J.M.: The Endocrinology of the critically ill. Curr. Opin. Endocrinol. Diab., 3, 138–145, 1996.
Imura H., Fukata J., Mori T.: Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems. Clin. Endocrinol., 35, 107–115, 1991.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gianotti, L., Broglio, F., Ramunni, J. et al. The activity of GH/IGF-I axis in anorexia nervosa and in obesity: A comparison with normal subjects and patients with hypopituitarism or critical illness. Eat Weight Disord 3, 64–70 (1998). https://doi.org/10.1007/BF03339990
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03339990